PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS
about
Current Concepts in Multiple Sclerosis: Autoimmunity Versus OligodendrogliopathyCharacteristics of disease and some exposure considerationsExercise therapy for fatigue in multiple sclerosisAnticholinergics for urinary symptoms in multiple sclerosisInformation provision for people with multiple sclerosisCarnitine for fatigue in multiple sclerosisFluoxetine for multiple sclerosisVaccines for preventing influenza in multiple sclerosis patientsExercise therapy for fatigue in multiple sclerosisDietary interventions for multiple sclerosisInformation provision for persons with multiple sclerosisVitamin D for the management of multiple sclerosisPlasma exchange for multiple sclerosisVitamin D for the management of multiple sclerosisCarnitine for fatigue in multiple sclerosisAcupuncture for multiple sclerosisAnticholinergics for urinary symptoms in multiple sclerosisCarnitine for fatigue in multiple sclerosisPsychological interventions for multiple sclerosisMultidisciplinary rehabilitation for adults with multiple sclerosisAmantadine for fatigue in multiple sclerosisExercise therapy for multiple sclerosisHyperbaric oxygen therapy for multiple sclerosisExercise therapy for multiple sclerosisApplication of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromesDiagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and SpacePossible clinical outcome measures for clinical trials in patients with multiple sclerosisOptic neuritis and multiple sclerosis.Data quality evaluation for observational multiple sclerosis registries.Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy.Multiple sclerosis, dental caries and fillings: a case-control study.The course of early-onset multiple sclerosis in Iraqi children.The radiologically isolated syndrome: look (again) before you treat.Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature.Interferon in relapsing-remitting multiple sclerosis.Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients.Non-parametric analysis of seasonality in birth and multiple sclerosis risk in second generation of migrants in Kuwait.Relationship between stress and relapse in multiple sclerosis: Part I. Important features.
P2860
Q22252578-0E76078C-318B-4809-AED7-69FDD17CE9EAQ23918973-D17B33B2-C7F1-4F4F-8CC2-6F82023A3C55Q24187235-B5F4A2B3-6C9E-4005-B2DC-0A399971B25FQ24187386-979C8B62-B4F5-40A4-8493-6E3C4E23E133Q24195040-6CB27223-0007-4B47-BE03-796E2617EE15Q24197748-FDE6ECA5-220C-4C9B-9D36-07DC5FF50DD9Q24198247-8E7E86D5-FC2D-41A1-A943-189B7831B109Q24201719-4E57B868-A4A4-4A1D-B06D-E63433F7E057Q24202399-6F1C2A4A-3ED6-4C2C-ACF1-C2A504B91B5AQ24202428-098483F1-8D59-4283-A109-CCCA132A8009Q24235042-6F51E907-D431-4A33-884B-9DACEE11A579Q24235702-7DED6CD7-1181-4376-A805-24861C778BA6Q24236418-4C0773FA-35DB-4D5A-BB73-83C6E29D0B8BQ24239892-F3B27044-7643-42B9-9030-8DE95ADC5A14Q24240036-4F21920E-F4A0-4E48-9DE8-3526101370EBQ24241139-E194B575-5089-457D-85C5-3BDD508DC7A5Q24241666-C48AD25D-201B-4D0B-BE45-7B90C6FFE499Q24242583-94CAE0B2-CCED-4221-8CB7-10B510AB6769Q24244909-5BBAAC06-E74D-40CF-A7F1-66EB0466728FQ24245311-A618CD09-92F7-4828-8797-0EA7AF3BBE0BQ24246259-0BA14EBD-A22A-4B91-B63A-4FAE74D7B78EQ24246736-685B2637-1B88-445F-AC23-08D2907CF282Q24247373-AD72F2C7-22B4-4CEF-AF85-BEDC2D3A8F3AQ24250331-13A3D373-3200-4C4F-AC49-A8DFD6D6D6E4Q28295788-5FD7106C-2B2E-4A00-A06E-40C83B0EC9EDQ29030707-D33AEA13-580B-496D-97CF-7A908C34FDBFQ30433837-A5EB0AE3-0F6C-4D44-8728-BD7AB389F593Q30654054-C1A1217E-DE53-47E0-BAFB-864C78AC2994Q31119031-4E8C52A0-5861-4DFE-9BD3-92780DDE8BF4Q33500910-9CB320D6-BB93-427E-ABF6-82D58AD3AF2EQ33645212-DA90701B-A76F-4ECB-A3E5-39AD8811AE4DQ33876879-34EEAA18-FB5A-4D32-A0FE-258D12FC4415Q33919855-06A31626-EC49-41F3-9575-B723EE8CC571Q33958206-5B5A084B-EC82-4968-94F7-17370F368205Q34396068-7A7C8C5F-C189-4074-8F28-131EF5F926FCQ34424659-9AF8BD33-5100-4CE7-B496-E4B3E8D88077Q34491595-4A886FF2-ED9C-49A3-BFD4-B580BDF73E02Q34513928-FDC88191-0002-45B9-93F0-1F6F1A308A2FQ34538571-2BB9D941-627C-4CCF-A451-80B8E522DBE4Q34569849-4DF3762A-6441-42CD-80A4-467645AB09B1
P2860
PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS
description
article
@en
im Dezember 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2006
@uk
name
PROBLEMS OF EXPERIMENTAL TRIAL ...... THERAPY IN MULTIPLE SCLEROSIS
@en
PROBLEMS OF EXPERIMENTAL TRIAL ...... THERAPY IN MULTIPLE SCLEROSIS
@nl
type
label
PROBLEMS OF EXPERIMENTAL TRIAL ...... THERAPY IN MULTIPLE SCLEROSIS
@en
PROBLEMS OF EXPERIMENTAL TRIAL ...... THERAPY IN MULTIPLE SCLEROSIS
@nl
prefLabel
PROBLEMS OF EXPERIMENTAL TRIAL ...... THERAPY IN MULTIPLE SCLEROSIS
@en
PROBLEMS OF EXPERIMENTAL TRIAL ...... THERAPY IN MULTIPLE SCLEROSIS
@nl
P2093
P1476
PROBLEMS OF EXPERIMENTAL TRIAL ...... THERAPY IN MULTIPLE SCLEROSIS
@en
P2093
Benedict Nagler
Fletcher McDowell
George A. Schumacher
Gilbert Beebe
John F. Kurtzke
Leonard T. Kurland
Robert F. Kibler
Thomas L. Willmon
Wallace W. Tourtellotte
William A. Sibley
P304
P356
10.1111/J.1749-6632.1965.TB20235.X
P577
2006-12-16T00:00:00Z